drugset / Trial / NCT01233375
Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether CO-1.01 is safe and effective for treating metastatic pancreatic cancer that did not respond to gemcitabine.
Timeline
- Start
- 2011-04
- Primary completion
- 2013-03
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | gemcitabine elaidate | Small molecule | 1250 mg/m2 | — |
| Subject | gemcitabine elaidate | Small molecule | 1400 mg/m2 | — |